Related Experiment Video
Updated: Jun 6, 2026
11:19
Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
Propofol and children--what we know and what we do not know
Ann E Rigby-Jones1, J Robert Sneyd
1Anaesthesia Research Group, Peninsula Medical School, Peninsula College of Medicine & Dentistry, University of Plymouth, Plymouth, UK. ann.rigby-jones@pms.ac.uk
Paediatric Anaesthesia
|November 19, 2010
Summary
Propofol pharmacokinetics are well-studied in children, with allometric scaling aiding predictions. However, pharmacodynamic data and pediatric anesthesia monitoring remain challenging, leaving key questions about children's sensitivity to propofol unanswered.
Area of Science:
- Anesthesiology
- Pharmacology
- Pediatric Medicine
Background:
- Propofol pharmacokinetics are well-established in pediatric populations.
- Allometric scaling is validated for predicting propofol disposition across species and pediatric development.
- Ontogenetic maturation in the first year of life necessitates adjustments to allometric models.
Purpose of the Study:
- To address the scarcity of pediatric propofol pharmacodynamic data.
- To investigate comparative sensitivity of children to propofol versus adults.
- To determine differences in time to peak effect in pediatric patients.
Main Methods:
- Utilized allometric scaling models for pharmacokinetic predictions.
- Employed time to peak effect techniques to determine K(eo) half-lives.
- Acknowledged limitations of current pediatric depth of anesthesia monitors.
Main Results:
- Allometric scaling models require specific adjustments for early infancy ontogeny.
- Pharmacodynamic data in children are limited due to practical and technological constraints.
- K(eo) half-lives for pediatric kinetic models have been determined.
Conclusions:
- Further research is needed to fully understand pediatric propofol pharmacodynamics.
- Current target-controlled infusion pumps do not incorporate determined pediatric K(eo) half-lives.
- Comparative sensitivity and time to peak effect in children remain areas for investigation.
Related Concept Videos
01:24Parenteral Anesthetics: Overview
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:20Inhalational Anesthetics: Overview
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...